CELZ Latest Press Releases

-- August 20, 2026 --

Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning Globe Newswire 9:15 AM

-- August 6, 2026 --

Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz , CELZ-101 and CELZ-201 Diabetes Platforms Globe Newswire 9:15 AM

-- July 1, 2026 --

Creative Medical Technology Holdings Issues Mid-Year Update Globe Newswire 9:00 AM

-- June 30, 2026 --

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds Globe Newswire 2:07 PM

-- June 22, 2026 --

Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain Globe Newswire 9:15 AM

-- June 16, 2026 --

Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards Globe Newswire 9:00 AM

-- April 28, 2026 --

Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies Globe Newswire 9:01 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software